PROMISE 006:Ⅳ期非小细胞肺癌中央型肺部肿瘤环周大分割姑息放疗(Quad Shot)Ⅰ期研究
改良3+3设计确定3个周期为最大耐受剂量,未出现系统性治疗中断,症状性患者报告呼吸困难、咳嗽和咯血改善率分别为67%、62%和100%。
要点
- 3个周期Quad Shot为最大耐受剂量,仅少数患者出现3级放疗相关毒性。
- 所有全身治疗均未因放疗中断,可与免疫或化疗同期进行。
- 症状性患者报告咯血改善100%、呼吸困难67%、咳嗽62%。
核心结论
- 3个周期Quad Shot的高级别毒性有限、不中断全身治疗且患者报告症状改善率高,可作为晚期NSCLC多学科姑息治疗选择。
主要发现
- 2周期队列发生1例剂量限制性毒性,3周期队列未发生,确立3周期为最大耐受剂量。
- 扩展队列中3例患者出现3级放疗相关毒性。
- 所有全身治疗均无中断完成。
- 症状性患者报告呼吸困难改善67%、咳嗽改善62%、咯血改善100%。
关键数值与推荐
- 每周期Quad Shot为14.8 Gy分4次,2个连续日内每日两次,在全身治疗后1周内完成。
- 剂量限制性毒性定义为发生率≤17%(6例中1例)。
- 允许的全身治疗包括单药免疫治疗、免疫联合化疗或单药化疗,由肿瘤内科医生决定。
临床怎么用
- 对Ⅳ期NSCLC中央型肺部肿瘤伴症状者,可考虑3周期Quad Shot姑息放疗并与全身治疗同期进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with stage IV non-small cell lung cancer (NSCLC) often present with substantial symptom burden that impairs quality of life and tolerance of systemic therapy. Quad Shot (QS), a cyclical hypofractionated radiation therapy (RT) regimen, could provide effective symptom palliation while allowing concurrent systemic therapy. We evaluated the safety, feasibility, and patient-reported outcomes of delivering up to 3 cycles of QS concurrently with systemic therapy. METHODS AND MATERIALS: This prospective phase I dose-escalation trial enrolled patients with stage IV NSCLC from June 2020 to February 2024. Allowable systemic therapy included immunotherapy alone, immunotherapy plus chemotherapy, or chemotherapy alone at the treating medical oncologist's discretion. Each QS cycle consisted of 14.8 Gy in 4 fractions delivered twice daily over 2 consecutive days within 1 week of systemic therapy. The primary endpoint was to determine the maximum tolerated number of QS cycles using a modified 3 + 3 design, defined as a dose-limiting toxicity rate ≤17% (1 of 6 patients). Secondary endpoints included feasibility, systemic therapy disruptions, RT-related toxicities, and patient-reported outcomes. RESULTS: Forty-five patients were enrolled in this study. One dose-limiting toxicity occurred in the 2-cycle cohort, and none occurred with 3 cycles, establishing 3 cycles as the maximum tolerated dose. In the expansion cohort, 3 patients developed grade 3 RT-related toxicities. All systemic therapies were administered without any interruptions. Among symptomatic patients, patient-reported outcomes demonstrated improvement in dyspnea (67%), cough (62%), and hemoptysis (100%). CONCLUSIONS: Three cycles of QS were associated with limited high-grade toxicities, no disruption of systemic therapy, and high rates of patient-reported symptom improvement, supporting its use as a palliative option within multidisciplinary care for advanced NSCLC.
引用
- Zhang YH, Iqbal A, Gelblum D, et al. A Phase I Study of Cyclical Hypofractionated Palliative Radiation Therapy (Quad Shot) for Central Lung Tumors in Patients With Stage IV Non-Small Cell Lung Cancer: Results From the PROMISE 006 Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42612834. doi:10.1016/j.ijrobp.2026.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。